Table 3.
Covariatea | Estimated Change (95% Confidence Interval) | P Value |
---|---|---|
DBP z score × V2b,c | −0.1% (−3.1% to 3.1%) | 0.97 |
DBP z score × V4 | 4.9% (1.0% to 8.9%) | 0.01 |
DBP z score × V6 | −1.1% (−6.7% to 4.8%) | 0.70 |
V4 versus V2 | −36.1% (−49.3% to −19.5%) | <0.001 |
V6 versus V2 | −33.1% (−55.2% to −0.1%) | 0.05 |
Average height (cm) × V2d,e | −0.5% (−0.8% to −0.3%) | <0.001 |
Average height (cm) × V4 | −0.2% (−0.5% to 0.0%) | 0.10 |
Average height (cm) × V6 | −0.3% (−0.6% to 0.1%) | 0.14 |
GFR | 0.0% (−0.1% to 0.1%) | 0.54 |
Female sex | −2.9% (−7.5% to 1.8%) | 0.22 |
African-American race | 6.4% (0.6% to 12.7%) | 0.03 |
Anemia | 6.7% (2.2% to 11.4%) | 0.003 |
ACEI or ARB | −0.9% (−5.3% to 3.6%) | 0.68 |
Other antihypertensive medication | 10.7% (3.1% to 18.9%) | 0.005 |
Visit is a categorical variable. Additional covariates in the model (nonsignificant) are age, CKD diagnosis, duration of CKD, and duration of CKD–visit interaction.
Overall test for DBP–visit interaction (P=0.07).
Slope of V2 DBP z score versus average of V4 and V6 DBP z score slopes (P=0.41).
Overall test for height–visit interaction (P=0.001).
Slope of V2 height versus average of V4 and V6 heights (P=0.002).